am -
pm ET,

Contact the Team

The Alnylam Assist® Team is comprised of individuals with diverse backgrounds and expertise in healthcare support and delivery.

How We Can Help

Alnylam Assist® Case Managers

Case Managers

Patients who start treatment with ONPATTRO® (patisiran) are partnered with a personal Alnylam Case Manager who can provide assistance with the following:

  • Benefit verification and explanation
  • Financial assistance for eligible patients*
  • Facilitation of product orders
  • Connection with a Field Reimbursement Director and/or a Patient Education Liaison

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Field Reimbursement Directors

Field Reimbursement Directors (FRDs) are experienced professionals who provide education about the ONPATTRO reimbursement process. FRDs can assist with:

  • Billing and coding requirements
  • Chart documentation best practices
  • Payer requirements
  • Payer issue identification and resolution
Alnylam Assist® Field Reimbursement Directors
Alnylam Assist® Patient Education Liaisons

Patient Education Liaisons

Patient Education Liaisons (PELs) have backgrounds in nursing or genetic counseling and are experienced in educating patients and their families about matters related to hereditary ATTR (hATTR) amyloidosis. PELs can help patients in a variety of ways, including:

  • Connecting patients to additional resources
  • Answering questions about treatment
  • Providing customized education, including one-on-one education and family meetings

Personalized Support Throughout the Treatment Process


Discover More

Patient Services

Learn more about how Alnylam Assist® supports
patients being treated with ONPATTRO® (patisiran).

Get the Facts

Forms and Documents

For more information about Alnylam Assist®
and treatment with ONPATTRO.

See Materials

Alnylam Assist® - Support Team

Take Action Now

Together with your patient (in office)

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).


ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.